RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer
Introduction: Immune checkpoint inhibitors (ICIs) are often associated with inflammatory toxicities known as immune-related adverse events (irAEs). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an atypical inflammatory arthritis. Herein, we report a case of RS3PE in a pa...
Main Authors: | Sang T. Kim, William A. Murphy Jr, Ana Aparicio, Sumit K. Subudhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Innovative Healthcare Institute
2020-08-01
|
Series: | Journal of Immunotherapy and Precision Oncology |
Subjects: | |
Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-20-2 |
Similar Items
-
Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
by: Bianca Gautron Moura, et al.
Published: (2022-12-01) -
Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
by: W. J. Mullally, et al.
Published: (2022-04-01) -
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
by: Scholz M, et al.
Published: (2017-03-01) -
Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
by: Amr Mohamed, et al.
Published: (2022-05-01) -
Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
by: Yusuke Kunimatsu, et al.
Published: (2023-04-01)